Your browser doesn't support javascript.
loading
A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia.
Gurnari, Carmelo; Wahida, Adam; Pagliuca, Simona; Durmaz, Arda; Zawit, Misam; Haferlach, Torsten; Maciejewski, Jaroslaw P; Visconte, Valeria.
Afiliación
  • Gurnari C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Wahida A; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Pagliuca S; Torsten-Haferlach Leukemia Diagnostics Foundation, Munich, Germany.
  • Durmaz A; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Zawit M; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Haferlach T; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Maciejewski JP; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Visconte V; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Hematol Oncol ; 40(4): 812-817, 2022 Oct.
Article en En | MEDLINE | ID: mdl-35106810
ABSTRACT
Telomere dysfunctions are associated with several hematopoietic stem cell (HSC) malignancies. Recent findings have indicated that the occurrence of rare variants of unknown significance (VUS) in the Telomerase Reverse Transcriptase (TERT) gene influences the outcomes of patients with myelodysplastic syndromes undergoing allogeneic HSC transplantation. However, the role of TERT variants has been historically controversial as initially considered pathogenic variants (H412Y, A202T) presenting functional consequences, were found very frequent in general population questioning their pathogenicity and risk allele significance. Herein, we show that overall TERT VUS are non-recurrent in myeloid disorders and cannot be considered risk alleles individually nor can their biological impact.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide / Telomerasa Límite: Humans Idioma: En Revista: Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide / Telomerasa Límite: Humans Idioma: En Revista: Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos